Related content

Asymmetric Dimethylarginine: a Novel Cardiovascular Risk Factor in End-stage Renal Disease

By Alsagaff M Yusuf   Thaha M   Aminuddin M   Yogiarto RM   Yogiantoro M   Tomino Y  

The Journal of International Medical Research, Vol. 40, Iss. 1, 2012-01 ,pp. : 340-349

Field House Publishing

Access to resources Recommend Favorite

Asymmetric Dimethylarginine (ADMA): A Promising Biomarker for Cardiovascular Disease?

By  

Current Topics in Medicinal Chemistry, Vol. 13, Iss. 2, 2013-01 ,pp. : 180-200

Bentham Science Publishers

Access to resources Recommend Favorite

Asymmetric dimethylarginine (ADMA) and the risk for coronary heart disease: the multicenter CARDIAC study

By Lenzen Henrike   Tsikas Dimitrios   Böger Rainer  

European Journal of Clinical Pharmacology, Vol. 62, Iss. 1, 2006-02 ,pp. : 45-49

Springer Publishing Company

Access to resources Recommend Favorite

"Sitagliptin dose adjustments are recommended for patients with moderate or severe RI [renal insufficiency] or ESRD [end-stage renal disease]"

By  

Inpharma, Vol. 1, Iss. 1601, 2007-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

The pharmacokinetics (PK) of aprepitant are not affected in patients with end-stage renal disease (ESRD) or severe renal impairment

By  

Inpharma, Vol. 1, Iss. 1494, 2005-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite